|
BR112018011414A2
|
|
method for producing n-retinoylaminoalkane sulfonic acid derivatives
|
|
WO2009078754A1
|
|
Drug delivery system for administration of poorly water soluble pharmaceutically active substances
|
|
WO2009078755A1
|
|
Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
|
|
WO2009078756A1
|
|
Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance
|
|
MY136047A
|
|
Novel potentiating compounds
|
|
EP1534672A1
|
|
Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
|
|
US7030158B2
|
|
Therapeutic compounds
|
|
CA2445478A1
|
|
Retinol derivatives potentiation of active substances by micellar preparation
|
|
EP1299400A1
|
|
Novel cytotoxic compounds and their use
|
|
MY128859A
|
|
Compounds for the treatment of cancer
|
|
WO0042832A2
|
|
New compounds for the treatment of cancer
|
|
EP1161436A1
|
|
Polyunsaturated fatty acid derivatives and their use in the treatment of cancer
|
|
US6197809B1
|
|
Compounds for the treatment of cancer
|
|
US6274747B1
|
|
Polyunsaturated fatty acid derivatives and their use
|
|
CA2335079A1
|
|
Composition for the treatement of immune deficiencies and methods for its preparation and use
|
